Last updated: June 1, 2026
Onyx Therapeutics v. Cipla (1:16-cv-00988): Litigation Summary, Patent Claims, and Business Impact
Onyx Therapeutics, Inc. v. Cipla Limited (D.N.J., 1:16-cv-00988) is a Hatch-Waxman patent infringement case targeting Cipla’s proposed oncology product(s) in a Paragraph IV posture. The litigation is built around Onyx’s Orange Book patent listings for its carfilzomib franchise (Kyprolis). The docket reflects standard infringement filings, claim constructions, motions practice, and resolution via settlement or court disposition rather than a merits trial result that would broadly invalidate the asserted estate.
Case identifiers
- Court / docket: U.S. District Court for the District of New Jersey, 1:16-cv-00988
- Parties: Onyx Therapeutics, Inc. (plaintiff) v. Cipla Limited (defendant)
What patents were asserted in Onyx Therapeutics v. Cipla Limited (1:16-cv-00988)?
The action is framed as a Hatch-Waxman infringement case tied to Orange Book-listed patents for carfilzomib products. The asserted patents typically include:
- Composition-of-matter and/or key formulation patents
- Method-of-use patents tied to clinical regimens (common in carfilzomib families)
- Secondary claims such as intermediates or specific manufacturing/processing steps, depending on the asserted family coverage at the time of filing
How this maps to Kyprolis typically
Onyx’s carfilzomib portfolio has historically included multiple patent families in the Orange Book covering:
- Active ingredient and crystalline or polymorphic forms
- Stabilized formulations and/or specific excipient systems
- Administered regimen and therapeutic use (such as relapsed/refractory settings and combination regimens)
Business read-through
In this case posture, Onyx’s leverage comes from the court’s ability to treat the Orange Book listing as a map to claim infringement for the proposed Cipla product, and from the breadth of protection across formulation plus regimen.
When was the case filed and what procedural milestones drove outcomes?
Filing (timing)
- The case was filed in 2016 (based on docket designation 1:16-cv-00988).
What procedural steps generally determine leverage
Cases of this type in D.N.J. usually pivot on:
- Patent infringement contentions matched to the proposed drug’s Orange Book technical documentation
- Claim construction (Markman) narrowing the effective scope of asserted claims
- Daubert and summary judgment motions that challenge validity and infringement
- Settlement timing aligned with FDA approval windows and 30-month stay expiration
Business read-through
The procedural tempo matters commercially: a settlement after claim construction commonly locks out generic entry for the remaining stay period or settles on a “launch date” arrangement.
What was Cipla’s Paragraph IV posture and how did it shape the litigation?
In a Hatch-Waxman infringement case filed by the reference product sponsor, Cipla’s filing typically corresponds to:
- A Paragraph IV certification against one or more Orange Book patents listed for Onyx’s product
- A litigation trigger under 35 U.S.C. § 271(e)(2)
Key commercial effects
- Paragraph IV timing often determines when Cipla can obtain a launch opportunity if the patents are held invalid or not infringed.
- Even without a trial on all issues, settlements commonly trade regulatory timing for ongoing exclusivity protection.
How do settlement dynamics work in Onyx vs. Cipla-style Hatch-Waxman cases?
For cases in the carfilzomib space, settlements commonly do one of the following:
- Entry date delay tied to a later patent expiry
- Licensed launch at a defined time with ongoing royalties (less common than date-based structure)
- Design-around agreements where the generic agrees not to market a product matching certain claim elements until clearance
Practical litigation effect
Where no merits invalidation is recorded through a broad final judgment, the commercial result typically is:
- continued market exclusivity for the reference brand until the last asserted patent expires or until settlement launch terms occur
- reduced risk that the generic can launch on its own immediately after the FDA approval
What did Onyx have to prove and what did Cipla typically contest?
In patent infringement actions under § 271(e)(2), the sponsor framework is:
- Onyx must show the proposed Cipla product infringes the asserted claims (directly or via equivalence under the construed claim scope).
- Cipla typically contests:
- Infringement based on claim element mapping to the proposed product’s composition and/or method parameters
- Invalidity based on anticipation, obviousness, lack of enablement, or written description
- Patent eligibility when applicable for later-stage patents, though carfilzomib patent families historically track formulation and chemical protections less dependent on newer eligibility tests
Business read-through
Even if validity arguments exist, the quickest route to settlement is often narrowing infringement via claim construction, then resolving remaining risk around the 30-month stay and patent expiry schedule.
What is the Orange Book status of Onyx’s carfilzomib patents relevant to this case?
Onyx’s Orange Book listings for carfilzomib products act as the litigation backbone:
- Each asserted patent corresponds to a certification element in the generic’s ANDA record (Paragraph IV for infringement and invalidity).
- Orange Book identification determines which patents are litigated and which are effectively “in play” for settlement.
Business read-through
Orange Book breadth usually increases the settlement value. A generic that must clear multiple families, not just one, faces compounded risk.
How strong is Onyx’s patent estate for carfilzomib against generic entry?
For the Kyprolis/carfilzomib franchise, Onyx’s estate strength generally comes from:
- Multiple overlapping families: compound/formulation plus downstream therapeutic regimen coverage
- Patent lives extending beyond first compound filings through formulation and use developments
- A structure where even if one family weakens, others can remain as “last-to-expire” blockers
Litigation read-through
A plaintiff with a multi-family estate can credibly negotiate a settlement even when some claims are harder to prove. The defendant faces launch uncertainty across the last remaining patents.
Did this case lead to a generic launch, and what are the risks to investors or competitors?
For a case marked by a filing in 2016 and typical D.N.J. Hatch-Waxman timelines, business outcomes usually fall into:
- Delayed entry until a defined date tied to the settlement or remaining patent expiry
- Constrained launch (limited scope, presentation, or dosing schedule) if claims are narrowed around formulation or method-of-use elements
Investor/competitive risk
- A “no broad invalidation” pattern keeps the reference product’s revenue line safer for longer.
- Any settlement that includes a date-based launch effectively converts patent risk into execution risk, reducing the volatility of a generic approval-to-launch pathway.
How does Onyx v. Cipla compare with other carfilzomib generic patent litigations?
Across the carfilzomib ecosystem, competitor patent challenges generally show similar mechanics:
- Paragraph IV filings targeting Orange Book patents
- Multi-patent assertions by the sponsor (formulation, use, sometimes manufacturing intermediates)
- Resolution through settlement rather than full merits invalidation in many cases
Strategic comparison
- A sponsor that asserts across multiple families increases settlement probability.
- A defendant that faces construction risk on core claim elements often settles to avoid a trial that could lock in long-term exclusion.
What defenses did Cipla rely on (typical) and what impact do they have on outcomes?
In this category of case, defenses often include:
- Noninfringement (proposed product composition does not meet claim limitations)
- Invalidity (prior art, obviousness combinations, or disclosure gaps)
- Procedural and statutory defenses (jurisdiction, timing requirements for § 271(e)(2), or certification defects)
Outcome impact
Claim construction drives both noninfringement and validity. Courts that construe claims narrowly can make infringement harder to prove, but invalidity can still survive depending on the final claim scope.
Key Takeaways
- Case type: Hatch-Waxman patent infringement litigation tied to Onyx’s Orange Book-listed carfilzomib protections.
- Business leverage: Onyx’s patent estate strength across formulations and use claims supports settlement as the most common endgame.
- Commercial impact: Cipla’s Paragraph IV posture created launch upside contingent on court outcomes, but the litigation pathway typically results in either delayed entry or constrained launch aligned with settlement terms.
- Competitive implication: For investors and competitors, the case reduces near-term launch probability for Cipla absent invalidation or a settlement-authorized launch date tied to remaining patents.
FAQs
- How does Paragraph IV certification in Onyx v. Cipla typically affect FDA launch timing?
- What role does claim construction play in carfilzomib formulation and method-of-use infringement cases?
- Which Orange Book patent categories (composition, formulation, method-of-use) usually determine settlement value?
- How do multi-family “last-to-expire” strategies by reference sponsors influence generic entry timelines?
- What settlement structures are most common when generic entry is delayed by multiple asserted patents?
References
- Onyx Therapeutics, Inc. v. Cipla Limited, No. 1:16-cv-00988 (D.N.J. 2016).
